📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-02 17:43
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Amanta Healthcare Commissions New SteriPort Line at Kheda Facility
Amanta Healthcare Limited has announced the commencement of commercial production at its new brownfield SteriPort facility located at its Kheda campus in Gujarat. The new automated line produces two-port IV containers designed for oncology and intensive care formulations with higher container integrity and reduced human intervention. The expansion is aimed at scaling operational efficiency and driving EBITDA margin expansion through higher-margin specialty parenteral products. This marks the operationalization of the company's core strategic growth driver, previously flagged as part of its INR 90 Cr SteriPort expansion program.
Confidence: HIGH
What changedAmanta Healthcare transitioned its new SteriPort line at the Kheda facility from development to active commercial production.
Why it mattersThe SteriPort segment commands higher negotiating power and margins compared to standard LVP/SVP lines, directly supporting the company's strategy to expand operating profitability.
Announcement Date: September 02, 2026Facility Type: BrownfieldLocation: Kheda, GujaratCapacity Addition (Units): not disclosed
📅 Short termPositive sentiment as a key capital project is successfully commissioned without reported delays.
📈 Long termEnhances the product mix toward higher-margin sterile injectables and oncology solutions, strengthening export capabilities and margin resilience.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Ramp-up timeline and capacity utilization rates post-commissioning
- Raw material price volatility (crude-derived plastic granules) affecting container packaging costs
Key Highlights
Commenced commercial production at the new SteriPort brownfield facility at the Kheda campus, Gujarat
Facility features advanced automation to reduce human interference and improve quality assurance in oncology and intensive care packaging
Management expects the high-value specialty line to drive operational efficiency and EBITDA margin expansion
Announcement released on September 02, 2026 pursuant to Regulation 30 of SEBI LODR
👀 What to Watch
Track capacity ramp-up and margin trajectory in upcoming quarterly financial results to evaluate the revenue and EBITDA contribution from the new SteriPort line.
Amanta Healthcare targets ₹120 cr peak revenue from new SteriPort line; production starts Aug 2026
Amanta Healthcare reported Q1 FY27 revenue of ₹69 cr, a 5% YoY growth, with EBITDA margins holding steady at 22% despite inflationary pressures. The company's ₹90 cr SteriPort expansion is nearing completion, with commercial production on Line 3 expected by late August 2026 after a one-quarter delay. This new line is projected to add ₹110-120 cr to the annual top line, nearly doubling SteriPort capacity to 12 crore bottles. Additionally, a 10.8 MW solar plant commissioned in June 2026 is expected to save ₹9 cr annually, supporting a targeted 4-5% EBITDA margin expansion.
Confidence: HIGH
What changedThe company confirmed a revised timeline for its SteriPort expansion (delayed from Q1 to Q2 FY27) and provided specific revenue and margin guidance for the new capacity.
Why it mattersThe ₹90 cr capex is highly material compared to current quarterly revenues (~₹69 cr), and the shift toward high-value SteriPort products (currently 44% of revenue) is critical for long-term margin improvement.
Q1 FY27 Revenue: ₹69 crSteriPort Peak Revenue (Annualized): ₹110-120 crSolar Power Savings: ₹9 cr per yearCapex Value: ₹90 crIncremental Depreciation: ₹6 cr annuallySteriPort Capacity Increase: 81.8%
📅 Short termThe stock may react positively to the concrete timeline for commercial production (late August 2026) and the expected margin benefits from the already-commissioned solar plant.
📈 Long termStructural shift towards higher-margin specialty products and lower energy costs could permanently re-rate the company's profitability profile over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk on the delayed SVP facility (Q4 FY27)
- Sensitivity to crude oil prices affecting polymer costs
- High dependence on short-term debt for working capital
Key Highlights
SteriPort capacity increasing from 6.6 crore to 12 crore bottles per year following a ₹90 cr capex
New SteriPort Line 3 expected to generate ₹110-120 crore in annualized peak revenue
10.8 MW captive solar project commissioned in June 2026 to save ₹9 crore in annual power costs
Management targets 4-5% EBITDA margin expansion driven by product mix and solar savings
SVP facility for high-margin export markets expected to commence operations in Q4 FY27
👀 What to Watch
Watch for the successful commercial ramp-up of SteriPort Line 3 in late August 2026 and the subsequent impact on Q2 FY27 margins to validate the 4-5% expansion guidance.
Amanta Healthcare Q1 FY27: Revenue at ₹69.45 Cr (up 4.8% YoY), PAT down 5.6% to ₹3.31 Cr
Amanta Healthcare reported a modest 4.8% YoY increase in total income from operations to ₹69.45 crore for the quarter ended June 30, 2026. However, net profit after tax declined by 5.6% YoY to ₹3.31 crore, down from ₹3.51 crore in the same period last year. Earnings per share (EPS) consequently fell to ₹0.85 from ₹1.22. The results indicate slight margin pressure as profit contracted despite the marginal revenue growth.
Confidence: HIGH
What changedThe company has released its unaudited financial results for the first quarter of FY27, showing marginal top-line growth but a decline in profitability.
Why it mattersThe results reflect the company's performance in a competitive parenteral business environment; the decline in PAT despite higher revenue suggests rising operating costs or pricing pressure.
Total Income (Q1 FY27): ₹69.45 crNet Profit (Q1 FY27): ₹3.31 crYoY Revenue Growth: 4.8%YoY PAT Growth: -5.6%Q1 Revenue vs FY26 Revenue: 23.86%
📅 Short termThe stock may remain range-bound or see slight pressure due to the year-on-year decline in net profit and EPS.
📈 Long termLong-term value depends on the successful ramp-up of high-value Steriport products and international market expansion to improve margins.
⚠ Risk flags
- Margin compression (PAT down despite revenue growth)
- Low pricing power in LVP/SVP segments
- Intense competition in the parenteral business
Key Highlights
Total income from operations grew 4.8% YoY to ₹69.45 crore in Q1 FY27.
Net profit after tax decreased to ₹3.31 crore from ₹3.51 crore in Q1 FY26.
Basic and Diluted EPS for the quarter stood at ₹0.85, down from ₹1.22 YoY.
Paid-up equity share capital increased to ₹3.88 crore from ₹2.88 crore in the year-ago quarter.
Total comprehensive income for the period was ₹3.13 crore, compared to ₹3.41 crore YoY.
👀 What to Watch
Investors should monitor the execution of the ₹90 crore Steriport capacity expansion, as current revenue growth (4.8%) is trailing the company's long-term target of 8-10%.
5.4% Revenue Growth in Q1FY27; ₹90 Cr Capacity Expansion on Track for Q2 Commissioning
Amanta Healthcare reported a steady Q1FY27 with revenue growing 5.4% YoY to ₹68.80 cr, driven by improved product mix. However, EBITDA margins compressed by 200 bps to 22% due to higher raw material and employee costs. PAT declined 5.6% YoY to ₹3.31 cr, primarily impacted by increased finance costs from a new solar term loan. The company confirmed that its Steriport plant is on track for Q2FY27 commissioning, which is a key trigger for future growth.
Confidence: HIGH
What changedThe company has transitioned from the planning phase to the final commissioning phase of its Steriport expansion while managing slight margin pressure from operational costs.
Why it mattersThe ₹90 cr capex is significant relative to the company's current revenue scale; successful execution will shift the product mix toward higher-value specialty segments like Steriport.
Q1FY27 Revenue: ₹68.80 crEBITDA Margin: 22%PAT Growth (YoY): -5.6%Planned Capex: ₹90 crCapex vs Annualized Revenue: ~33%
📅 Short termThe stock may see neutral to slightly cautious sentiment due to the margin dip and PAT decline, despite the revenue growth.
📈 Long termThe structural story depends on the ₹90 cr expansion; if the Steriport and SVP lines ramp up as planned by FY27-end, it could significantly re-rate the earnings profile.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Margin compression from raw material volatility
- Rising finance costs impacting net profitability
- Execution risk on the remaining SVP expansion timeline
Key Highlights
Revenue increased to ₹68.80 cr in Q1FY27 from ₹65.31 cr in Q1FY26.
EBITDA margin moderated to 22% from 24% in the previous year's corresponding quarter.
PAT stood at ₹3.31 cr, down from ₹3.50 cr, due to higher interest expenses.
Steriport facility commissioning is expected within Q2FY27 (July-Sept 2026).
Small Volume Parenteral (SVP) expansion is targeted for completion by Q4FY27.
👀 What to Watch
Watch for the successful commissioning and utilization levels of the Steriport facility in the next quarterly update, as this capacity is critical for margin expansion.
Amanta Healthcare Targets 20%+ Revenue CAGR; Commissioning Major Capacity in FY27
Amanta Healthcare has outlined a significant growth roadmap in its Q1FY27 presentation, targeting a 20%+ revenue CAGR and 25%+ EBITDA margins. The company is in the final stages of a major capacity expansion, adding 5.39 Cr SteriPort units and 10.78 Cr SVP units with commissioning expected in Q2 and Q4 of FY27. Financial health has improved with the debt-to-equity ratio dropping from 3.50x in FY23 to 1.06x in FY26. Additionally, a 10.8 MW solar plant is expected to generate annual savings of ₹9 Cr, directly impacting the bottom line.
Confidence: HIGH
What changedThe company has provided a concrete timeline for its capacity commissioning and formalized aggressive margin and growth targets for the next cycle.
Why it mattersThe shift toward high-margin SteriPort (ISBM technology) and cost-saving solar energy represents a structural move to improve profitability and pricing power in the parenteral segment.
SteriPort Capacity Addition: 5.39 Cr unitsSVP Capacity Addition: 10.78 Cr unitsExpected Solar Savings: ₹9 Cr per annumDebt-to-Equity (FY26): 1.06xCWIP vs FY26 Revenue: ~125%
📅 Short termThe market is likely to react positively to the clear commissioning timelines and the substantial reduction in debt levels.
📈 Long termIf the company achieves its 25% EBITDA margin target through specialty products and energy savings, it could lead to a significant re-rating of the stock.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for the new production lines
- Volatility in crude oil prices affecting plastic granule costs
- High working capital cycle of 141 days
Key Highlights
Scaling SteriPort capacity by 5.39 Cr units and SVP capacity by 10.78 Cr units in FY27
Targeting 20%+ Revenue CAGR and 25%+ EBITDA margins compared to 22.8% in FY26
Commissioning of 10.8 MW solar captive power plant expected to save ₹9 Cr annually
Debt-to-Equity ratio significantly reduced to 1.06x in FY26 from 3.50x in FY23
Capital Work-in-Progress (CWIP) surged to ₹82 Cr in FY26 from ₹7 Cr in FY25, indicating imminent capacity additions
👀 What to Watch
Investors should track the successful commissioning of the SteriPort expansion in Q2FY27 and the SVP expansion in Q4FY27 to validate the projected 20% growth trajectory.
Amanta Healthcare Approves Q1 FY27 Results; 31st AGM Set for Sept 16, 2026
Amanta Healthcare's board has approved the financial results for the quarter ended June 30, 2026, with an unmodified audit opinion. The company has scheduled its 31st Annual General Meeting (AGM) for September 16, 2026. Additionally, the board dissolved the IPO Committee, which was originally formed in August 2024, signaling the completion of its specific mandate. These developments follow a fiscal year (FY26) where the company reported revenue of ₹65.31 crore and a PAT of ₹3.51 crore.
Confidence: HIGH
What changedThe company has finalized its Q1 FY27 performance review and set the timeline for its annual shareholder meeting, while formally ending the tenure of its IPO oversight committee.
Why it mattersThe meeting confirms the company's transition into a post-IPO phase and provides the schedule for shareholder engagement. The dissolution of the IPO committee suggests administrative processes related to the listing are concluded.
FY26 Revenue: ₹65.31 crPlanned Capex: ₹90 crCapex vs FY26 Revenue: 137.8%AGM Date: September 16, 2026
📅 Short termThe stock may see routine movement as investors digest the Q1 results and the upcoming AGM details.
📈 Long termThe structural focus remains on the ₹90 crore Steriport expansion and the company's ability to scale high-value products in international markets like Cambodia and Zimbabwe.
⚠ Risk flags
- High dependence on short-term debt
- Sensitivity to crude oil prices affecting plastic granule costs
- Low pricing power in LVP/SVP segments due to NPPA regulations
Key Highlights
Approved financial results for the quarter ended June 30, 2026, with an unmodified audit report.
Scheduled the 31st Annual General Meeting (AGM) for September 16, 2026, via video conferencing.
Dissolved the IPO Committee effective August 05, 2026, which was originally constituted on August 24, 2024.
FY26 annual revenue was ₹65.31 crore with an operating profit margin of 22.81%.
Company is currently executing a ₹90 crore capacity expansion in the Steriport segment, representing ~138% of FY26 revenue.
👀 What to Watch
Investors should review the detailed Q1 FY27 financial statements once published to assess if the 8-10% growth target is being met and track the progress of the ₹90 crore Steriport expansion.
Amanta Healthcare Promoter Bhavesh Patel Acquires Shares via Open Market
Amanta Healthcare Limited has informed the exchanges that Shri Bhavesh Girishbhai Patel, a member of the promoter group, has purchased equity shares of the company from the open market. The disclosure was made on June 22, 2026, in compliance with Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Such open-market purchases by promoters are typically viewed as a sign of confidence in the company's current valuation and future growth prospects.
Key Highlights
Promoter Bhavesh Girishbhai Patel executed an open-market purchase of equity shares.
Disclosure filed under SEBI (Prohibition of Insider Trading) Regulations, 2015.
The transaction was officially reported to BSE and NSE on June 22, 2026.
Insider buying often signals that management believes the stock is undervalued or expects positive developments.
👀 What to Watch
Investors should take this as a positive signal of promoter confidence, though they should also monitor the upcoming quarterly shareholding pattern to see the exact percentage increase in promoter stake.
Promoter Bhavesh Girishbhai Patel Acquires Shares of Amanta Healthcare via Open Market
Amanta Healthcare Limited has informed the exchanges that Shri Bhavesh Girishbhai Patel, a member of the promoter group, has purchased equity shares of the company through the open market. The disclosure was filed on June 18, 2026, under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Such open-market purchases by promoters are generally viewed as a sign of confidence in the company's long-term value and future prospects.
Key Highlights
Promoter Shri Bhavesh Girishbhai Patel purchased equity shares via the open market.
Disclosure submitted in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.
The notification was officially recorded by the company on June 18, 2026.
The transaction involves Amanta Healthcare Limited (BSE: 544502, NSE: AMANTA).
👀 What to Watch
Investors should monitor the specific quantity and price of shares purchased in the detailed Form C filing to gauge the strength of the promoter's conviction. Promoter buying is typically a bullish indicator for the stock.
Amanta Healthcare Promoter Group Member Kirit Ambalal Desai Sells Shares in Open Market
Amanta Healthcare Limited has reported a regulatory disclosure regarding the sale of equity shares by a member of its promoter group. Shri Kirit Ambalal Desai executed an open-market sale of shares, as per the filing under SEBI (Prohibition of Insider Trading) Regulations, 2015. The disclosure was submitted to the exchanges on June 17, 2026, following the receipt of Form C from the promoter group member. Investors should monitor if this divestment is an isolated event or part of a larger trend in promoter stake reduction.
Key Highlights
Disclosure filed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
Transaction involves an open-market sale of equity shares by promoter group member Kirit Ambalal Desai.
The company officially notified both BSE and NSE regarding the transaction on June 17, 2026.
The filing confirms the submission of Form C detailing the disposal of holdings.
👀 What to Watch
Investors should review the full Form C filing to determine the exact volume of shares sold and the impact on the total promoter holding percentage. While individual sales can be for personal liquidity, consistent selling by the promoter group can be a signal to exercise caution.
Amanta Healthcare Commissions 10.8 MWp Solar Power Plant for Captive Consumption
Amanta Healthcare Limited has successfully commissioned a 10.8 MWp solar power plant located in Kheda, Gujarat. The facility is designed for captive consumption, which is expected to significantly reduce the company's electricity expenses and overall operational costs. All necessary regulatory approvals have been secured, and power generation officially commenced on May 30, 2026. This initiative enhances the company's sustainability profile while potentially improving operating margins over the long term.
Key Highlights
Successfully commissioned a 10.8 MWp solar power plant in Village Baroda, Kheda district.
The plant is dedicated to captive consumption to lower operational and energy costs.
Power generation and operations officially started on May 30, 2026.
All requisite regulatory approvals for the project have been received.
👀 What to Watch
Investors should monitor the company's upcoming quarterly financial results to quantify the reduction in power and fuel expenses and the resulting impact on EBITDA margins.
Amanta Healthcare Reports Zero Deviation in ₹126 Crore IPO Fund Utilization for Q4 FY26
Amanta Healthcare Limited has confirmed that there were no deviations or variations in the utilization of the ₹126 crore raised through its IPO in September 2025. As of March 31, 2026, the company has deployed ₹47.66 crore toward setting up a new manufacturing line for SteriPort in Kheda, Gujarat. Notably, actual issue expenses were ₹22.85 crore, which was ₹3.58 crore higher than initially estimated, resulting in a corresponding reduction in the budget for General Corporate Purposes. No funds have been utilized yet for the Small Volume Parenterals (SVP) manufacturing line project.
Key Highlights
Total IPO proceeds of ₹126 crore raised with zero reported deviation from the objects of the issue.
₹47.66 crore utilized for the SteriPort manufacturing line against a total allocation of ₹70 crore.
Actual issue expenses reached ₹22.85 crore, exceeding the initial estimate of ₹19.26 crore by ₹3.58 crore.
General Corporate Purposes allocation was revised downward to ₹3.02 crore to offset higher issue costs.
The ₹30.13 crore allocation for the SVP manufacturing line remains unutilized as of the quarter ended March 2026.
👀 What to Watch
Investors should track the execution timeline of the SteriPort and SVP manufacturing lines, as these capacity expansions are critical for future revenue growth. The lack of deviation indicates disciplined financial management of IPO proceeds.
Amanta Healthcare FY26 PAT Jumps 42% to ₹15 Cr; Capacity Expansion to 12 Cr Bottles Underway
Amanta Healthcare reported a robust FY26 performance with revenue reaching INR 288 crores and a significant 42% growth in PAT to INR 15 crores. The company is nearly doubling its SteriPort capacity from 6.6 crore to 12 crore bottles per year to meet rising demand in critical care and oncology. Operational efficiency is expected to improve further with the commissioning of a 10.8 MW captive solar plant and a strengthened balance sheet where the debt-to-equity ratio has improved from 3x to 1x.
Key Highlights
FY26 Revenue grew 5% to INR 288 crores with EBITDA margins stable at 22% (INR 63 crores)
Full-year PAT increased by 42% YoY to INR 15 crores, while Q4 PAT rose 28% to INR 5.5 crores
SteriPort capacity is expanding from 6.6 crore to 12 crore bottles per year, with commissioning expected next month
Debt-to-equity ratio significantly improved from 3x to 1x over the last three years
A 10.8 MW captive solar power project is set for commissioning within days to reduce energy costs from FY27
👀 What to Watch
Investors should monitor the ramp-up of the new SteriPort capacity and the resulting operating leverage in FY27. The company's successful deleveraging and focus on high-value segments like inhalation and ophthalmics provide a strong foundation for long-term growth.
Amanta Healthcare Approves FY26 Financial Results and Updates Governance Policies
Amanta Healthcare Limited announced the approval of its financial results for the quarter and full year ending March 31, 2026, during its board meeting on May 19, 2026. The company's statutory auditors, Price Waterhouse Chartered Accountants LLP, issued an unmodified opinion, confirming the reliability of the financial statements. Furthermore, the board approved revisions to the Code of Conduct for Prevention of Insider Trading and the Whistle Blower Policy. These administrative updates are aimed at strengthening internal controls and maintaining high standards of corporate governance.
Key Highlights
Board approved standalone financial results for the quarter and year ended March 31, 2026
Statutory auditors Price Waterhouse Chartered Accountants LLP issued an unmodified audit opinion
Revision of the Code of Conduct for Prevention of Insider Trading approved by the board
Whistle Blower Policy updated to enhance corporate governance frameworks
The board meeting concluded within approximately 3 hours (12:15 PM to 03:10 PM)
👀 What to Watch
Investors should review the detailed financial statements on the company's website to assess specific growth metrics for FY26. The unmodified audit opinion and policy updates indicate a stable regulatory and governance environment.
Amanta Healthcare Approves FY26 Financial Results with Unmodified Audit Opinion
Amanta Healthcare's Board of Directors approved the standalone financial results for the quarter and full year ended March 31, 2026, during their meeting on May 19, 2026. A significant highlight is that the statutory auditors, Price Waterhouse Chartered Accountants LLP, issued an unmodified opinion, suggesting no major accounting concerns. The board also updated key governance frameworks, including the Insider Trading and Whistle Blower policies. While specific revenue and profit figures were not detailed in this announcement, the clean audit report is a positive indicator of financial transparency.
Key Highlights
Board approved standalone financial results for the quarter and year ended March 31, 2026.
Statutory auditors Price Waterhouse Chartered Accountants LLP issued an unmodified opinion.
Revision and approval of the Code of Conduct for Prevention of Insider Trading.
Update to the Whistle Blower Policy to strengthen corporate governance.
The board meeting concluded at 3:10 P.M. following a nearly three-hour session.
👀 What to Watch
Investors should review the detailed financial statements on the exchange website to evaluate specific growth in revenue and margins. The unmodified audit opinion provides a layer of assurance regarding the company's financial reporting integrity.
Amanta Healthcare FY26 PAT Surges 42% to ₹14.88 Cr; Q4 Revenue Up 7%
Amanta Healthcare reported a steady FY26 with revenue growing 4.7% to ₹287.68 crore and a significant 41.7% jump in Net Profit to ₹14.88 crore. The bottom-line growth was primarily driven by reduced finance costs and improved operating leverage, despite a slight dip in Q4 EBITDA margins from 24% to 22%. The company is currently undergoing major capacity expansions in its SteriPort and SVP segments to drive future growth. Management remains focused on high-margin products and operational efficiencies through a new captive solar project.
Key Highlights
FY26 Net Profit increased by 41.7% YoY to ₹14.88 crore, with PAT margins improving from 4% to 5%.
Annual Revenue grew 4.7% YoY to ₹287.68 crore, while Q4 revenue rose 6.8% to ₹76.99 crore.
Q4 PAT saw a 28% YoY increase to ₹5.53 crore, supported by lower finance costs and operational discipline.
FY26 EBITDA stood at ₹63.23 crore with a stable margin of 22% for the full year.
Major capacity expansion in progress for SteriPort and SVP segments to target domestic and export markets.
👀 What to Watch
Investors should monitor the progress of the ongoing capacity expansions as they are critical for accelerating revenue growth beyond the current single-digit levels. The significant improvement in earnings quality and reduced finance costs are positive indicators for long-term value creation.
Amanta Healthcare FY26: 11% Revenue CAGR, Debt-to-Equity Drops to 1.06x, Massive Capex Underway
Amanta Healthcare's FY26 presentation highlights a steady 11% Revenue CAGR and a significant financial turnaround, with Debt-to-Equity falling from 3.43x to 1.06x. The company is operating at near-peak capacity with 96% utilization, prompting a ₹130 Cr capex to expand SteriPort and SVP lines by FY27. Management is targeting aggressive growth with a 20%+ Revenue CAGR and 25%+ EBITDA margins over the next two years, supported by efficiency measures like a 10.8 MW solar plant.
Key Highlights
Debt-to-Equity ratio significantly improved from 3.43x in FY23 to 1.06x in FY26 through NCD repayments.
SteriPort (LVP) capacity to expand from 6.62 Cr to 11.6 Cr bottles by FY27, targeting ₹110-120 Cr incremental revenue.
Total asset utilization reached 96% in FY26, necessitating a ₹130 Cr capex plan for FY26-27.
Installation of a 10.8 MW solar captive power plant expected to generate annual cost savings of ₹9 Cr.
Management guidance targets 20%+ Revenue CAGR and 25%+ EBITDA margins for the next two fiscal years.
👀 What to Watch
Investors should monitor the timely commissioning of the new production lines in FY27 and the subsequent margin expansion. The sharp reduction in leverage and high asset utilization suggest a well-managed transition into a high-growth phase.
Amanta Healthcare Promoter Bhavesh Patel Acquires 28,800 Shares via Open Market
Shri Bhavesh Patel, the Promoter, Chairman, and Managing Director of Amanta Healthcare, has purchased 28,800 equity shares of the company. These transactions were conducted through the open market on March 27 and March 30, 2026. The disclosure was made in compliance with SEBI (Prohibition of Insider Trading) Regulations. Such insider buying by the top-most executive is generally perceived as a strong signal of confidence in the company's future performance and valuation.
Key Highlights
Promoter and CMD Shri Bhavesh Patel acquired 28,800 equity shares from the open market.
The acquisition took place across two trading sessions on March 27 and March 30, 2026.
Disclosure filed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
The purchase reflects management's direct financial commitment to the company's growth trajectory.
👀 What to Watch
Investors should take this as a positive cue regarding the company's internal outlook. It is advisable to monitor if the promoter continues to increase their stake in subsequent quarters.
Amanta Healthcare Promoter Bhavesh Patel Acquires 48,151 Shares via Open Market
Shri Bhavesh Patel, a promoter of Amanta Healthcare Limited, has increased his stake by purchasing 48,151 equity shares from the open market. The acquisition took place over two trading sessions on February 26 and February 27, 2026. This transaction was disclosed under the SEBI (Prohibition of Insider Trading) Regulations, 2015. Such insider buying typically signals strong promoter confidence in the company's future prospects and intrinsic value.
Key Highlights
Promoter Shri Bhavesh Patel purchased a total of 48,151 equity shares.
The acquisition was conducted through open market transactions on February 26 and 27, 2026.
The disclosure was filed in compliance with Regulation 7(2) of SEBI Insider Trading rules.
The move indicates increased 'skin in the game' by the promoter group.
👀 What to Watch
Investors should view this promoter buying as a positive sign of internal confidence, though it should be weighed against the company's overall financial performance.
CRISIL Upgrades Amanta Healthcare’s Long-Term Rating to 'BBB/Stable' on Improved Financial Profile
CRISIL has upgraded Amanta Healthcare's long-term rating to 'BBB/Stable' and short-term rating to 'A3+', reflecting a significantly strengthened financial position. The upgrade follows a successful IPO that raised Rs 126 crore, boosting net worth to Rs 211 crore as of September 2025 and reducing gearing from 2.02 to 0.84. The company maintains healthy operating margins of 21-22% and is expanding capacity for its Steriport and SVP brands, expected to go live in April 2026. This improved credit profile suggests lower borrowing costs and better financial stability for future growth.
Key Highlights
Long-term credit rating upgraded to 'CRISIL BBB/Stable' from 'CRISIL BBB-/Stable' for Rs 245 crore bank facilities.
Net worth increased to Rs 211 crore from Rs 96 crore following a Rs 126 crore IPO infusion.
Debt-to-equity (gearing) ratio improved significantly to 0.84x from 2.02x as of September 2025.
Operating margins remain healthy at approximately 22% for the first half of fiscal 2026.
Capacity expansion for Steriport and SVP brands is scheduled for completion by April 2026 to drive future revenue.
👀 What to Watch
Investors should view this upgrade as a sign of reduced financial risk and improved balance sheet strength following the IPO. Monitor the timely commencement of the new capacity in April 2026 as it is the primary catalyst for medium-term growth.
Amanta Healthcare Q3 PAT Rises 8.1%; Targets ₹150 Cr Incremental Revenue from Expansion
Amanta Healthcare reported a steady Q3 FY26 with revenue growing 9.8% YoY to ₹75 crores and PAT increasing 8.1% to ₹5 crores. The company is nearing a major growth phase, doubling its SteriPort capacity to 12 crore bottles per annum with commercialization expected in April 2026. Management anticipates an incremental revenue potential of ₹150 crores from the combined LVP and SVP expansions. Additionally, a 10.8 MW captive solar plant is expected to save ₹9 crores annually starting Q1 FY27, which will significantly enhance operating leverage.
Key Highlights
Q3 FY26 revenue grew 9.8% YoY to ₹75 crores, while 9M PAT surged 51% YoY to ₹9 crores.
SteriPort capacity doubling to 12 crore bottles/year with commercialization slated for April 2026.
Total incremental revenue potential of ₹150 crores from SteriPort and SVP expansions.
10.8 MW captive solar plant to be commissioned by Q1 FY27, targeting ₹9 crores in annual cost savings.
EBITDA margins remained healthy at 21.3% for the 9-month period despite one-time IPO expenses.
👀 What to Watch
Investors should monitor the successful ramp-up of the new SteriPort capacity in April 2026 as it is the primary driver for the projected ₹150 crore revenue growth. The stock remains attractive for long-term investors given the improving return ratios and structural cost advantages from the upcoming solar project.
